Premium
End‐stage liver disease: Management of hepatorenal syndrome
Author(s) -
Mauro Ezequiel,
GarciaOlveira Lucrecia,
Gadano Adrián
Publication year - 2021
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14866
Subject(s) - terlipressin , hepatorenal syndrome , medicine , cirrhosis , liver disease , creatinine , kidney disease , gastroenterology , model for end stage liver disease , acute kidney injury , bolus (digestion) , intensive care medicine , liver transplantation , transplantation
Hepatorenal syndrome (HRS) is a serious complication of cirrhosis with high morbidity and mortality rates. Recently, the definition of HRS type 1 has been updated and is now called HRS‐AKI. This new definition reduces the risk of delaying HRS treatment and eliminates the need to establish a minimum creatinine cut‐off for the diagnosis of HRS‐AKI. From a pathophysiological point of view, newly identified mechanisms involved in the development of HRS are related to the inflammatory response, conditioning the development of extrahepatic organ dysfunction in patients with cirrhosis. One of the main challenges for the diagnosis of HRS is the validation of new biomarkers to obtain an early and differential diagnosis of kidney injury (eg HRS vs. ATN). Treatment of HRS is based on the use of vasoconstrictive agents in combination with albumin and terlipressin is the most widely used vasoconstrictor drug, with a high response rate. The effects of a continuous infusion of terlipressin at a dose of 2‐12 mg/day was similar to bolus administration, but with lower rates of adverse events. Finally, MELD/MELD‐Na which includes creatinine as one of its main determinants gives AKI‐HRS patients priority on the waiting list (WL) for liver transplant (LT). However, the MELD and MELD‐Na scores are reduced in responding patients, resulting a longer waiting time in these patients than in non‐responders. Thus, the initial MELD/MELD‐Na score (pre‐treatment value) should be used to prioritize patients on the WL for LT in these cases.